[go: up one dir, main page]

WO2006037383A8 - Piscirickettsia salmonis antigens and use thereof - Google Patents

Piscirickettsia salmonis antigens and use thereof

Info

Publication number
WO2006037383A8
WO2006037383A8 PCT/EP2005/003615 EP2005003615W WO2006037383A8 WO 2006037383 A8 WO2006037383 A8 WO 2006037383A8 EP 2005003615 W EP2005003615 W EP 2005003615W WO 2006037383 A8 WO2006037383 A8 WO 2006037383A8
Authority
WO
WIPO (PCT)
Prior art keywords
present
discloses
srs
antigens
piscirickettsia salmonis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/003615
Other languages
French (fr)
Other versions
WO2006037383A1 (en
Inventor
Michel Thiry
Ingrid Dheur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2004/003339 external-priority patent/WO2005035558A2/en
Priority claimed from IE20040674A external-priority patent/IE20040674A1/en
Application filed by Individual filed Critical Individual
Priority to AU2005291622A priority Critical patent/AU2005291622A1/en
Priority to CA002615139A priority patent/CA2615139A1/en
Priority to EP05736851A priority patent/EP1794185A1/en
Priority to US11/660,023 priority patent/US20110171251A1/en
Publication of WO2006037383A1 publication Critical patent/WO2006037383A1/en
Anticipated expiration legal-status Critical
Priority to NO20072240A priority patent/NO20072240L/en
Publication of WO2006037383A8 publication Critical patent/WO2006037383A8/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention discloses novel proteins, e.g., antigens, from Piscirickettsia salmonis. The present invention further discloses nucleic acids that encode these proteins. The present invention also discloses the use of the proteins, e.g., antigens, and nucleic acids to prepare vaccines against salmonid rickettsial septicemia (SRS). The present invention further provides recombinant Yersinia ruckeri cells to be used to construct vaccines against SRS. The present invention also discloses vaccines that to can be used to protect fish from Piscirickettsia salmonis, as well as other pathogens. In addition, the present invention discloses methods of using the vaccines of the present invention to protect fish from SRS as well as from other pathogenic diseases.
PCT/EP2005/003615 2004-10-01 2005-04-05 Piscirickettsia salmonis antigens and use thereof Ceased WO2006037383A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2005291622A AU2005291622A1 (en) 2004-10-01 2005-04-05 Piscirickettsia salmonis antigens and use thereof
CA002615139A CA2615139A1 (en) 2004-10-01 2005-04-05 Piscirickettsia salmonis antigens and use thereof
EP05736851A EP1794185A1 (en) 2004-10-01 2005-04-05 Piscirickettsia salmonis antigens and use thereof
US11/660,023 US20110171251A1 (en) 2004-10-01 2005-04-05 Piscirickettsia salmonis antigens and use thereof
NO20072240A NO20072240L (en) 2004-10-01 2007-04-30 Antigens from piscirickettsia salomius and their use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/IB2004/003339 WO2005035558A2 (en) 2003-10-07 2004-10-01 Piscirickettsia salmonis antigens and use thereof
IBPCT/IB2004/003339 2004-10-01
IE2004/0674 2004-10-05
IE20040674A IE20040674A1 (en) 2003-10-07 2004-10-05 Piscirickettsia salmonis antigens and use thereof

Publications (2)

Publication Number Publication Date
WO2006037383A1 WO2006037383A1 (en) 2006-04-13
WO2006037383A8 true WO2006037383A8 (en) 2007-12-21

Family

ID=34965943

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/003615 Ceased WO2006037383A1 (en) 2004-10-01 2005-04-05 Piscirickettsia salmonis antigens and use thereof

Country Status (5)

Country Link
EP (1) EP1794185A1 (en)
AU (1) AU2005291622A1 (en)
CA (1) CA2615139A1 (en)
DK (1) DK200700656A (en)
WO (1) WO2006037383A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008337440B2 (en) * 2007-12-19 2013-05-02 Intervet International B.V. Vaccine antigens from Piscirickettsia salmonis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068865A2 (en) * 2000-03-11 2001-09-20 Novartis Ag Fish vaccine against piscirickettsia salmonis
EP1334197B1 (en) * 2000-11-11 2011-01-05 The University Court of The University of Aberdeen Yeast derived vaccine against ipnv
AU2004279610B2 (en) * 2003-10-07 2010-02-25 Ingrid Dheur Piscirickettsia salmonis antigens and use thereof

Also Published As

Publication number Publication date
AU2005291622A1 (en) 2006-04-13
WO2006037383A1 (en) 2006-04-13
DK200700656A (en) 2007-05-01
EP1794185A1 (en) 2007-06-13
CA2615139A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
WO2005035558A3 (en) Piscirickettsia salmonis antigens and use thereof
WO2009077577A3 (en) Vaccine antigens from piscirickettsia salmonis
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
WO2007054279A3 (en) Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
WO2006078294A3 (en) Alphavirus vectors for respiratory pathogen vaccines
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
WO2007130493A3 (en) Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
WO2006014292A3 (en) Oral vaccine for borrelia
WO2010074575A3 (en) Recombinant classical swine fever virus (csfv) comprising a modified e2 protein and methods for generating said recombinant csfv.
WO2006110728A3 (en) Immunogenic cmv tegument aggregates
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
WO2006038908A3 (en) Ancestral and cot viral sequences, proteins and immunogenic compositions
WO2008103819A3 (en) Chimeric newcastle disease virus vlps
MXPA05005202A (en) Vaccine.
JP2020523001A5 (en)
WO2007098717A3 (en) Chimeric vaccine antigens against classical swine fever virus
EP1613345A4 (en) Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
EA200970731A1 (en) HUMAN CYTOMEGALOVIRUS RECOMBINANT ANTIGENS (HCMV)
WO2007052059A3 (en) Changing th1/th2 balance in split influenza vaccines with adjuvants
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
WO2006136460A3 (en) New adjuvant
DE60143810D1 (en) VAKZINE AGAINST IPNV TO BE ISOLATED FROM HEFEZELLEN

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005736851

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005291622

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2615139

Country of ref document: CA

ENP Entry into the national phase in:

Ref document number: 2005291622

Country of ref document: AU

Date of ref document: 20050405

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005291622

Country of ref document: AU

NENP Non-entry into the national phase in:

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005736851

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11660023

Country of ref document: US